{"id":"NCT02497976","sponsor":"ICStudy, LLC","briefTitle":"Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis","officialTitle":"Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-15","primaryCompletion":"2017-04-16","completion":"2017-07-12","firstPosted":"2015-07-15","resultsPosted":"2018-03-22","lastUpdate":"2018-05-17"},"enrollment":42,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystitis, Interstitial"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab pegol","otherNames":["Cimzia"]},{"type":"DRUG","name":"Placebo","otherNames":["Normal saline"]}],"arms":[{"label":"Group 1: Experimental","type":"ACTIVE_COMPARATOR"},{"label":"Group 2: Placebo Comparator","type":"PLACEBO_COMPARATOR"}],"summary":"A Randomized, Double-blind, Placebo Controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome","primaryOutcome":{"measure":"IC/BPS Symptoms Change With Overall Global Response Assessment (GRA)","timeFrame":"Week 2","effectByArm":[{"arm":"Group 1: Experimental","deltaMin":2,"sd":null},{"arm":"Group 2: Placebo Comparator","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23792149","24958479"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":28},"commonTop":["urinary infection"]}}